
Estimate Adjusted EBIT Margin

	Fiscal Year Ending					LTM
	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Jun-25
(USD in millions)	FY-4	FY-3	FY-2	FY-1	FY	LTM

Revenue	4	5	19	7	12	5

Adjusted EBITDA Build-up
EBT, Incl. Unusual Items	(16)	(42)	(32)	(42)	(24)	(28)
(+) Net Interest Expense	0	1	(0)	(3)	(3)	(3)
(+) Other Non Operating Exp.	1	(2)	(3)	1	(2)	2
(+) D&A	0	0	1	1	0	0
(+) Non-recurring Items					4	2
Adjusted EBITDA	(14)	(43)	(34)	(43)	(25)	(26)

(-) D&A	(0)	(0)	(1)	(1)	(0)	(0)

Adjusted EBIT	(15)	(44)	(35)	(43)	(26)	(26)
% of Revenue	-391.6%	-815.2%	-179.7%	-641.1%	-215.3%	-521.8%


	Low	Median	High

Adjusted EBIT Margin	0.0%	0.0%	0.0%

支援算式

Equity Waterfall


Equity Waterfall

	Model
(USD in millions)	Low	Mid	High	Market
Enterprise Value	11	28	71	(9)
(+) Cash & Short Term Investments	56	56	56	56
(+) Investments & Other	0	0	0	0
(-) Debt	0	0	0	0
(-) Other Liabilities	0	0	0	0
(-) Preferred Stock	0	0	0	0
(-) Other	0	0	0	0
Value of Common Equity	67	84	128	47
(/) Shares Outstanding	33.0	33.0	33.0	33.0
Implied Stock Price (USD)	2.02	2.54	3.86	1.42
FX Rate: USD/EUR	1.17	1.17	1.17	1.17
Implied Stock Price (EUR)	1.72	2.16	3.30	1.21

Upside / (Downside)	42.50%	78.85%	172.46%


Stock Price	1.21
Stock Price Close	1.21
Restatment Type	Original
Reporting Currency	USD
Trading Currency	EUR
FX Rate: USD/EUR	1.17
Market Cap	34.3
Shares Outstanding	26.3
Share Exchange Ratio	1.3
Liquid Long-term Investments	0

載入錯誤

LAVA Therapeutics N.V.